Andre Choulika Ph.D.

Andre Choulika Ph.D. is a prominent figure in the biotechnology industry, particularly in the field of gene editing and cancer immunotherapy. Here's a comprehensive overview of his professional background:

Professional Experience

Chief Executive Officer at Cellectis: Andre Choulika is the founder, Chairman, and CEO of Cellectis, a biopharmaceutical company he established in December 1999.1 Cellectis focuses on developing novel cancer therapies using engineered T-cells, particularly for treating leukemias and solid tumors.1

Board Member at Institut Pasteur: Since June 2019, Choulika has been serving as a Member of the Board of Directors at Institut Pasteur in Paris, France.1

Educational Background

Choulika's academic credentials include:

• Ph.D. in Molecular Virology from Université Pierre et Marie Curie (1985-1995)1
• Post-Doctoral Fellowship at Harvard Medical School, Department of Genetics and Molecular Medicine (1997-1999)1
• Management training from HEC School of Management (Challenge+ program, 2000-2001)1

Research and Expertise

Dr. Choulika is recognized for his work in genome engineering, particularly:

• Developing approaches for meganuclease-based human gene therapy while at Boston Children's Hospital1
• Expertise in TALEN™, meganucleases, and electroporation technology Pulsagile1
• Pioneering allogeneic T-cell chimeric antigen receptor (CAR) technology for cancer immunotherapy1

Industry Leadership

Beyond his role at Cellectis, Choulika has been actively involved in the biotechnology sector:

• Served as President of France Biotech, the French biotechnology association, for over four years1
• Contributes to the advancement of cell and gene therapy research2

Andre Choulika's work at Cellectis has been focused on developing innovative cancer treatments that aim to reduce toxicities associated with current chemotherapeutics and potentially offer curative therapies.1 His leadership has guided Cellectis in its mission to create a new generation of cancer immunotherapy, capitalizing on the company's extensive expertise in genome engineering.1